Gabor B Brenner
Overview
Explore the profile of Gabor B Brenner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
238
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gergely T, Kovacs T, Kovacs A, Toth V, Sayour N, Morotz G, et al.
ESC Heart Fail
. 2024 Nov;
PMID: 39535377
Background: Cardiac remodelling, a crucial aspect of heart failure, is commonly investigated in preclinical models by quantifying cardiomyocyte cross-sectional area (CSA) and microvascular density (MVD) via histological methods, such as...
2.
Sayour N, Gergely T, Varadi B, Toth V, Agg B, Kovacs T, et al.
ESC Heart Fail
. 2024 Sep;
12(1):87-100.
PMID: 39243187
Aims: Heart failure with reduced ejection fraction (HFrEF) is a leading cause of death worldwide; thus, therapeutic improvements are needed. In vivo preclinical models are essential to identify molecular drug...
3.
Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2
Chen S, Wang Q, Bakker D, Hu X, Zhang L, van der Made I, et al.
Basic Res Cardiol
. 2024 Jul;
119(5):751-772.
PMID: 39046464
Sodium glucose cotransporter 2 inhibitors (SGLT2i) constitute the only medication class that consistently prevents or attenuates human heart failure (HF) independent of ejection fraction. We have suggested earlier that the...
4.
Kovacshazi C, Hambalko S, Sayour N, Gergely T, Brenner G, Pelyhe C, et al.
Sci Rep
. 2024 May;
14(1):12016.
PMID: 38797778
Hypercholesterolemia (HC) induces, propagates and exacerbates cardiovascular diseases via various mechanisms that are yet not properly understood. Extracellular vesicles (EVs) are involved in the pathomechanism of these diseases. To understand...
5.
Sayour N, Brenner G, Makkos A, Kiss B, Kovacshazi C, Gergely T, et al.
Cardiovasc Res
. 2023 Jan;
119(6):1336-1351.
PMID: 36718529
Aims: Remote ischaemic preconditioning (RIPC) is a robust cardioprotective intervention in preclinical studies. To establish a working and efficacious RIPC protocol in our laboratories, we performed randomized, blinded in vivo...
6.
Gergely T, Brenner G, Nagy R, Sayour N, Makkos A, Kovacshazi C, et al.
Int J Mol Sci
. 2023 Jan;
24(2).
PMID: 36675100
Lipid-lowering drugs have been shown to have cardioprotective effects but may have hidden cardiotoxic properties. Therefore, here we aimed to investigate if chronic treatment with the novel lipid-lowering drug bempedoic...
7.
Weber B, Brenner G, Kiss B, Gergely T, Sayour N, Tian H, et al.
Pharmaceuticals (Basel)
. 2022 Sep;
15(9).
PMID: 36145276
Clinical observations are highly inconsistent with the use of the antidiabetic rosiglitazone regarding its associated increased risk of myocardial infarction. This may be due to its hidden cardiotoxic properties that...
8.
Hegyesi H, Pallinger E, Mecsei S, Hornyak B, Kovacshazi C, Brenner G, et al.
Cell Mol Life Sci
. 2022 Jan;
79(2):84.
PMID: 35059851
The release of extracellular vesicles (EVs) is increased under cellular stress and cardiomyocyte damaging conditions. However, whether the cardiomyocyte-derived EVs eventually reach the systemic circulation and whether their number in...
9.
Voros I, Saghy E, Pohoczky K, Makkos A, Onodi Z, Brenner G, et al.
Front Pharmacol
. 2021 Nov;
12:663655.
PMID: 34803662
Little is known about the role of the neuropeptide somatostatin (SST) in myocardial ischemia/reperfusion injury and cardioprotection. Here, we investigated the direct cardiocytoprotective effect of SST on ischemia/reperfusion injury in...
10.
Onodi Z, Ruppert M, Kucsera D, Sayour A, Toth V, Koncsos G, et al.
Cardiovasc Res
. 2021 Jun;
117(13):2639-2651.
PMID: 34117866
Aims: Interleukin-1β (IL-1β) is an important pathogenic factor in cardiovascular diseases including chronic heart failure (HF). The CANTOS trial highlighted that inflammasomes as primary sources of IL-1 β are promising...